Optos Given “Buy” Rating at N+1 Singer (OPTS)
Optos (LON:OPTS)‘s stock had its “buy” rating restated by research analysts at N+1 Singer in a report released on Tuesday, American Banking and Market News reports. They currently have a GBX 260 ($4.27) price target on the stock. N+1 Singer’s price objective would indicate a potential upside of 33.50% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Panmure Gordon raised their price target on shares of Optos from GBX 206 ($3.38) to GBX 235 ($3.86) in a research note to investors on Friday, January 17th. They now have a “buy” rating on the stock. Separately, analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Optos in a research note to investors on Friday, December 13th. They now have a GBX 300 ($4.92) price target on the stock, up previously from GBX 180 ($2.95). Finally, analysts at Canaccord Genuity cut their price target on shares of Optos from GBX 248 ($4.07) to GBX 231 ($3.79) in a research note to investors on Monday, November 25th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 252.67 ($4.15).
Shares of Optos (LON:OPTS) traded down 2.62% during mid-day trading on Tuesday, hitting GBX 194.75. The stock had a trading volume of 87,368 shares. Optos has a 1-year low of GBX 106.75 and a 1-year high of GBX 221.00. The stock’s 50-day moving average is GBX 193.0 and its 200-day moving average is GBX 164.9. The company’s market cap is £140.6 million.
Optos Plc is a retinal imaging company. The Company’s medical devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina in a single capture.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.